ADVANCED ENZYME TECHNOLOGIES Financial Statement Analysis
|
||
|
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 17.09% YoY .
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 28.58 % YoY. |
||
ADVANCED ENZYME TECHNOLOGIES Last 5 Annual Financial Results
[BOM: 540025|NSE : ADVENZYMES]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹746 Cr | ₹637 Cr | ₹624 Cr | ₹541 Cr | ₹529 Cr |
| Expenses | ₹516 Cr | ₹441 Cr | ₹419 Cr | ₹383 Cr | ₹327 Cr |
| Operating Profit (Excl OI) | ₹229 Cr | ₹196 Cr | ₹205 Cr | ₹158 Cr | ₹203 Cr |
| Other Income | ₹36 Cr | ₹33 Cr | ₹37 Cr | ₹25 Cr | ₹6.42 Cr |
| Interest | ₹3.73 Cr | ₹4.63 Cr | ₹4.12 Cr | ₹3.48 Cr | ₹2.96 Cr |
| Depreciation | ₹40 Cr | ₹37 Cr | ₹35 Cr | ₹35 Cr | ₹35 Cr |
| Profit Before Tax | ₹233 Cr | ₹187 Cr | ₹188 Cr | ₹140 Cr | ₹171 Cr |
| Profit After Tax | ₹174 Cr | ₹134 Cr | ₹137 Cr | ₹104 Cr | ₹124 Cr |
| Consolidated Net Profit | ₹169 Cr | ₹131 Cr | ₹133 Cr | ₹106 Cr | ₹120 Cr |
| Earnings Per Share (Rs) | ₹15.07 | ₹11.72 | ₹11.92 | ₹9.45 | ₹10.70 |
| PAT Margin (%) | 23.24 | 21.03 | 21.92 | 19.18 | 23.34 |
| ROE(%) | 11.43 | 9.79 | 10.72 | 8.94 | 12.04 |
| ROCE(%) | 15.27 | 13.76 | 14.78 | 12.26 | 16.66 |
| Total Debt/Equity(x) | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 |
Key Financials |
||
| Market Cap | : | ₹ 2,985.9 Cr |
| Revenue (TTM) | : | ₹ 749.6 Cr |
| Net Profit(TTM) | : | ₹ 171.8 Cr |
| EPS (TTM) | : | ₹ 15.3 |
| P/E (TTM) | : | 17.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ADVANCED ENZYME TECHNOLOGIES | -2.3% | -11% | -19.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.4% | -6.6% | 7.3% |
| DIVIS LABORATORIES | 1.2% | -2.6% | 60% |
| TORRENT PHARMACEUTICALS | -2% | -6.1% | 33% |
| CIPLA | -2.3% | -5.8% | -13.9% |
| DR REDDYS LABORATORIES | -1.1% | 3.8% | -5.5% |
| MANKIND PHARMA | -4.5% | 2.7% | -2.1% |
| LUPIN | -2.5% | -7.2% | -1.5% |
| ZYDUS LIFESCIENCES | -2.1% | -3% | 12.8% |
ADVANCED ENZYME TECHNOLOGIES Revenues
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 17.09 % |
| 5 Yr CAGR | 8.94 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹746 Cr | 17.09 | |
| Mar2025 | ₹637 Cr | 2.09 | |
| Mar2024 | ₹624 Cr | 15.39 | |
| Mar2023 | ₹541 Cr | 2.13 | |
| Mar2022 | ₹529 Cr | - | |
ADVANCED ENZYME TECHNOLOGIES Operating Profit
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 17.26 % |
| 5 Yr CAGR | 3.14 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹229 Cr | 17.26 | |
| Mar2025 | ₹196 Cr | -4.79 | |
| Mar2024 | ₹205 Cr | 30.38 | |
| Mar2023 | ₹158 Cr | -22.25 | |
| Mar2022 | ₹203 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 0.13 % |
| 5 Yr CAGR | -5.33 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 30.74% | 0.13 | |
| Mar2025 | 30.7% | -6.72 | |
| Mar2024 | 32.91% | 12.98 | |
| Mar2023 | 29.13% | -23.88 | |
| Mar2022 | 38.27% | - | |
ADVANCED ENZYME TECHNOLOGIES Profit After Tax
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 28.68 % |
| 5 Yr CAGR | 8.99 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹169 Cr | 28.68 | |
| Mar2025 | ₹131 Cr | -1.64 | |
| Mar2024 | ₹133 Cr | 26.19 | |
| Mar2023 | ₹106 Cr | -11.66 | |
| Mar2022 | ₹120 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 10.51 % |
| 5 Yr CAGR | -0.11 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 23.24 % | 10.51 | |
| Mar2025 | 21.03 % | -4.06 | |
| Mar2024 | 21.92 % | 14.29 | |
| Mar2023 | 19.18 % | -17.82 | |
| Mar2022 | 23.34 % | - | |
ADVANCED ENZYME TECHNOLOGIES Earnings Per Share (EPS)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 28.58 % |
| 5 Yr CAGR | 8.94 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹15 | 28.58 | |
| Mar2025 | ₹12 | -1.68 | |
| Mar2024 | ₹12 | 26.14 | |
| Mar2023 | ₹9.45 | -11.68 | |
| Mar2022 | ₹11 | - | |
ADVANCED ENZYME TECHNOLOGIES Return on Capital Employed (ROCE)
[BOM: 540025|NSE : ADVENZYMES]
| Y-o-Y | 10.97 % |
| 5 Yr CAGR | -2.15 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 15.27% | 10.97 | |
| Mar2025 | 13.76% | -6.90 | |
| Mar2024 | 14.78% | 20.55 | |
| Mar2023 | 12.26% | -26.41 | |
| Mar2022 | 16.66% | - | |
ADVANCED ENZYME TECHNOLOGIES Share Price vs Sensex
| Current Share Price | : | ₹266.6 |
| Current MarketCap | : | ₹ 2,985.9 Cr |
| Updated EOD on | : | Oct 09,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ADVANCED ENZYME TECHNOLOGIES | -2.3% |
-11% |
-19.9% |
| SENSEX | 0.8% |
-4.8% |
-10.5% |
ADVANCED ENZYME TECHNOLOGIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -0.2% | -5.5% | -4.1% |
| BSE HEALTHCARE | -2.2% | -4.8% | 12.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY TOTAL MARKET | -0% | -5.5% | -4% |
| NIFTY SMALLCAP 500 | -0.4% | -4.6% | NA |
| NIFTY MICROCAP 250 | -1.5% | -3.9% | 10.1% |
You may also like the below Video Courses
FAQ about ADVANCED ENZYME TECHNOLOGIES Financials
How the annual revenues of ADVANCED ENZYME TECHNOLOGIES have changed ?
The Revenues of ADVANCED ENZYME TECHNOLOGIES have increased by 17.09% YoY .
How the Earnings per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES have changed?
The Earnings Per Share (EPS) of ADVANCED ENZYME TECHNOLOGIES has increased by 28.58 % YoY .
Check out Intrinsic Value of Peers of ADVANCED ENZYME TECHNOLOGIES
Compare Stock Analytics of Peers of ADVANCED ENZYME TECHNOLOGIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
